Compare
Carlsmed, Inc. vs Apyx Medical Corp vs TriSalus Life Sciences, Inc. vs SANUWAVE Health, Inc.
| Latest fiscal year | Carlsmed, Inc. CARL | Apyx Medical Corp APYX | TriSalus Life Sciences, Inc. TLSI | SANUWAVE Health, Inc. SNWV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $50.51M | $52.84M | $45.15M | $44.05M |
| Revenue growth (YoY) | +85.9% | +9.9% | +53.4% | +35.0% |
| Gross margin | 75.3% | 62.5% | 84.6% | 77.1% (computed) |
| Operating margin | -60.5% | -12.2% | -59.7% | 11.2% |
| Net margin | -58.7% | -21.2% | -86.9% | 26.8% |
| Net income | -$29.63M | -$11.21M | -$39.23M | $11.81M |
| EPS (Diluted) | -$2.12 | n/a | -$1.84 | $0.41 |
| Operating cash flow | -$28.98M | -$8.00M | -$18.01M | $3.88M |
| Free cash flow | -$29.62M | -$9.12M | -$18.93M | $1.93M |
| Cash & equivalents | $85.79M | $31.74M | $20.44M | $11.96M |
| Total assets | $130.12M | $66.84M | $35.33M | $37.34M |
| Total liabilities | $31.25M | $52.01M | $69.19M | $35.72M |
| Shareholders' equity | $98.87M | $14.54M | -$33.86M | $1.62M |
| Return on year-end equity | -30.0% | -77.1% | n/a | 729.6% |
| Shares outstanding | 26.60M | 41.79M | 50.00M | 8.59M |
Revenue, most recent five fiscal years
| Fiscal year | Carlsmed, Inc. | Apyx Medical Corp | TriSalus Life Sciences, Inc. | SANUWAVE Health, Inc. |
|---|---|---|---|---|
| Latest | $50.51M Ended 2025-12-31 | $52.84M Ended 2025-12-31 | $45.15M Ended 2025-12-31 | $44.05M Ended 2025-12-31 |
| 1 year earlier | $27.16M Ended 2024-12-31 | $48.10M Ended 2024-12-31 | $29.43M Ended 2024-12-31 | $32.63M Ended 2024-12-31 |
| 2 years earlier | n/a | $52.35M Ended 2023-12-31 | $18.51M Ended 2023-12-31 | $20.40M Ended 2023-12-31 |
| 3 years earlier | n/a | $44.51M Ended 2022-12-31 | $12.40M Ended 2022-12-31 | $16.74M Ended 2022-12-31 |
| 4 years earlier | n/a | $48.52M Ended 2021-12-31 | n/a | $13.01M Ended 2021-12-31 |